Active Ingredient (In Each Tablet)
Loratadine USP 10 mg
The following Structured Product Label (SPL) was submitted to the FDA by Chain Drug Consortium, Llc for the product Loratadine Odt (NDC 68016-088). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient (in each tablet), purpose, uses, do not use, ask a doctor before use if you have, when using this product, stop use and ask a doctor if, if pregnant or breast-feeding,, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Loratadine USP 10 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
if you have ever had an allergic reaction to this product or any of its ingredients.
liver or kidney disease. Your doctor should determine if you need a different dose.
do not take more than directed. Taking more than directed may cause drowsiness.
an allergic reaction to this product occurs. Seek medical help right away.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
| adults and children 6 years and over | 1 tablet daily; not more than 1 tablet in 24 hours |
| children under 6 years of age | ask a doctor |
| consumers with liver or kidney disease | ask a doctor |
aspartame, crospovidone, mannitol, microcrystalline cellulose, peppermint, pregelatinized starch (maize), sodium stearyl fumarate
call 1-855-274-4122
NDC 68016-088-10
**Compare to the active ingredient
in Claritin® RediTabs®
Original Prescription Strength
Non-Drowsy*
Premier Value ®
Loratadine Orally Disintegrating Tablets USP 10 mg
Allergy Relief
Antihistamine
Indoor & Outdoor Allergies
No Water Needed Melts in Your Mouth
24 Hour Relief of:
10 Orally Disintegrating Tablets
*When taken as directed. See Drug Facts Panel.
* Please review the disclaimer below.